Self-Reported Health Related Quality of Life (HRQoL) in Patients With Ischemic Heart Disease: A Randomized Controlled Trial on Digital Health Pharmacist Interventions
Author(s)
Umm-e- Kalsoom, MPhil1, Amjad Khan, PhD2, Yu Fang, PhD2.
1Quaid-i-Azam University, Islamabad, Pakistan, 2Xi’an Jiaotong University, Xi’an, China.
1Quaid-i-Azam University, Islamabad, Pakistan, 2Xi’an Jiaotong University, Xi’an, China.
OBJECTIVES: Digital health programs have been suggested as one possible framework to improve health related quality of life (HRQoL) through combing them with pharmacy services. This study investigates the impact of a digital health pharmacy interventions (DHPIs) on self-reported HRQoL and quality-adjusted life years (QALYs) in patients with Ischemic heart disease.
METHODS: One-year follow-up randomized controlled trial was conducted from September, 2023 to August, 2024, at the Punjab Institute of Cardiology in Lahore. Adults with IHD (n = 332) were randomly allocated to either the intervention group (n = 166) or the control group (n = 166). The responses were evaluated using two validated questionnaires, namely the SF-12 and EQ-5D-5L. The McNemar Test, independent-sample T test, multivariate analysis of variance and principal component analysis models were used to analyze the data. The p value less than 0.05 value was considered as a significant.
RESULTS: The study results showed that 119 (48%) female and 129 (52.01%) male completed the one year’ follow-up study and 36% were above 60 years old. The HRQoL of ischemic patients in intervention group showed a significant improvement over time with mean ± standard deviation value of 30.81±12.42 at baseline, while 38.94±20.13 at 6 months and 43.53±16.26 at 12 months, suggesting a sustain change during follow-up study. Moreover, DHPIs has a 75% impact on overall health, 97% on mental health, 91% on physical health, and 88% on social health for ischemic patients. During the past 6 to 12 months, 23% IHD patients felt pain interfering normal routine and almost 60 % patients felt energy in intervention group.
CONCLUSIONS: The study findings showed a significant improvement in HRQoL and health utility scores of patients with IHD suggesting that the implementation of DHPIs may an effective strategy for management of IHD.
METHODS: One-year follow-up randomized controlled trial was conducted from September, 2023 to August, 2024, at the Punjab Institute of Cardiology in Lahore. Adults with IHD (n = 332) were randomly allocated to either the intervention group (n = 166) or the control group (n = 166). The responses were evaluated using two validated questionnaires, namely the SF-12 and EQ-5D-5L. The McNemar Test, independent-sample T test, multivariate analysis of variance and principal component analysis models were used to analyze the data. The p value less than 0.05 value was considered as a significant.
RESULTS: The study results showed that 119 (48%) female and 129 (52.01%) male completed the one year’ follow-up study and 36% were above 60 years old. The HRQoL of ischemic patients in intervention group showed a significant improvement over time with mean ± standard deviation value of 30.81±12.42 at baseline, while 38.94±20.13 at 6 months and 43.53±16.26 at 12 months, suggesting a sustain change during follow-up study. Moreover, DHPIs has a 75% impact on overall health, 97% on mental health, 91% on physical health, and 88% on social health for ischemic patients. During the past 6 to 12 months, 23% IHD patients felt pain interfering normal routine and almost 60 % patients felt energy in intervention group.
CONCLUSIONS: The study findings showed a significant improvement in HRQoL and health utility scores of patients with IHD suggesting that the implementation of DHPIs may an effective strategy for management of IHD.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD101
Topic
Clinical Outcomes, Health Service Delivery & Process of Care, Patient-Centered Research
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), No Additional Disease & Conditions/Specialized Treatment Areas